pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,079 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
    Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a submission to the FDA.
    STAT · 2mo ago↗ source
  • STAT+: ‘No drama’ Diamantas should serve biotech well as acting FDA chief
    Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the agency.
    STAT · 2mo ago↗ source
  • STAT+: Treatment for alcohol addiction is undergoing a seismic shift. Many say it’s overdue
    The surging popularity of alternatives to Alcoholics Anonymous represents a seismic shift in the alcohol treatment landscape. Many say it's overdue.
    STAT · 2mo ago
← prev
page 30 of 44
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
↗ source
  • Opinion: Using AI in addiction medicine could be particularly risky
    "AI can make great strides in medical decision support, but unfiltered interaction between agent and patient is dangerous," writes Steve D. Klein.
    STAT · 2mo ago↗ source
  • <![CDATA[Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast Cancer]]>
    <![CDATA[Breast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies]]>
    <![CDATA[Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond. ]]>
    onclive · 2mo ago↗ source
  • Hantavirus risk remains low, CDC says, citing its ‘playbook’ response
    Despite rising concern about the hantavirus outbreak on a cruise ship, two CDC doctors say the risk to the public remains low.
    STAT · 2mo ago↗ source
  • <![CDATA[Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice]]>
    <![CDATA[Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.]]>
    onclive · 2mo ago↗ source
  • Officials say $1.3 billion in Medicaid money to California will be deferred over suspicions of fraud
    Vice President JD Vance announced a $1.3 billion deferral in Medicaid reimbursements to California, as part of an initiative to root out fraud in federal health programs.
    STAT · 2mo ago↗ source
  • Opinion: The hantavirus is a wake-up call. Will the Trump administration answer it?
    Arriving in the isolation ward of a biocontainment hospital is an unsettling, scary experience. In 2014, I spent 19 days in one while being treated for Ebola, watching the news…
    STAT · 2mo ago↗ source
  • <![CDATA[FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML]]>
    <![CDATA[The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma]]>
    <![CDATA[The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML]]>
    <![CDATA[Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia. ]]>
    onclive · 2mo ago↗ source
  • Opinion: Hospitals are silencing doctors online, and it’s fueling the health misinformation crisis
    Hospitals and health systems need to loosen the reins and let physicians combat social media misinformation, writes Adam Goodcoff.
    STAT · 2mo ago↗ source
  • <![CDATA[Tirabrutinib and CAR T-Cell Therapy Represent Potential Paradigm Shifts in R/R PCNSL ]]>
    <![CDATA[Ashley Sumrall, MD, FACP, FASCO, discusses emerging data for tirabrutinib and the evolving role of CAR T-cell therapy in primary central nervous system lymphoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Future Directions in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono conclude the discussion by reflecting on the evolving future of radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mC…
    onclive · 2mo ago↗ source
  • <![CDATA[Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the increasing complexity of personalized treatment decision-making in metastatic castration-resistant prostate cancer (mCRPC) as radiopharm…
    onclive · 2mo ago↗ source
  • STAT+: What the Trump administration wants in its next FDA leader
    Leaders want the next FDA commissioner to be someone who can rebuild trust, focus on food policy, and drive drug-approval reforms.
    STAT · 2mo ago↗ source
  • <![CDATA[Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss the future direction of radiopharmaceutical therapies and emerging treatment strategies in metastatic castration-resistant prostate cancer (…
    onclive · 2mo ago↗ source
  • <![CDATA[Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss practical approaches to monitoring and managing toxicities associated with radiopharmaceutical therapies in metastatic castration-resistant…
    onclive · 2mo ago↗ source
  • <![CDATA[Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castr…
    onclive · 2mo ago↗ source
  • <![CDATA[Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of treatment sequencing and patient selection for radiopharmaceuticals in metastatic castration-resistant prostate cancer…
    onclive · 2mo ago↗ source
  • <![CDATA[Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics influence the use of radiopharmaceuticals in metastatic castration-resistant prostate canc…
    onclive · 2mo ago↗ source
  • <![CDATA[Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus o…
    onclive · 2mo ago↗ source
  • <![CDATA[Consensus Recommendations Address Key Controversies in Lymphoma Management]]>
    <![CDATA[Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.]]>
    onclive · 2mo ago↗ source